These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 27041994)

  • 1. Cost-effectiveness comparison of lamivudine plus adefovir combination treatment and nucleos(t)ide analog monotherapies in Chinese chronic hepatitis B patients.
    Zhang C; Ke W; Liu L; Gao Y; Yao Z; Ye X; Zhou S; Yang Y
    Drug Des Devel Ther; 2016; 10():897-910. PubMed ID: 27041994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China.
    Ke W; Zhang C; Liu L; Gao Y; Yao Z; Ye X; Zhou S; Yang Y
    Hepatol Int; 2016 Nov; 10(6):924-936. PubMed ID: 27271357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness Comparison Between the Response-Guided Therapies and Monotherapies of Nucleos(t)ide Analogues for Chronic Hepatitis B Patients in China.
    Lai K; Zhang C; Ke W; Gao Y; Zhou S; Liu L; Yang Y
    Clin Drug Investig; 2017 Mar; 37(3):233-247. PubMed ID: 27928739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China.
    Wu B; Shen J; Cheng H
    BMC Health Serv Res; 2012 Nov; 12():385. PubMed ID: 23137013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tenofovir
    Rodríguez M; Pascasio JM; Fraga E; Fuentes J; Prieto M; Sánchez-Antolín G; Calleja JL; Molina E; García-Buey ML; Blanco MÁ; Salmerón J; Bonet ML; Pons JA; González JM; Casado MÁ; Jorquera F;
    World J Gastroenterol; 2017 Nov; 23(41):7459-7469. PubMed ID: 29151700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy.
    Park JG; Park SY
    Clin Mol Hepatol; 2015 Sep; 21(3):242-8. PubMed ID: 26523269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective.
    Dakin H; Sherman M; Fung S; Fidler C; Bentley A
    Pharmacoeconomics; 2011 Dec; 29(12):1075-91. PubMed ID: 22077579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response.
    Woo HY; Park JY; Bae SH; Kim CW; Jang JY; Tak WY; Kim DJ; Kim IH; Heo J; Ahn SH
    Clin Mol Hepatol; 2020 Jul; 26(3):352-363. PubMed ID: 32460460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of adefovir plus entecavir combination therapy in patients with chronic hepatitis B refractory to both lamivudine and adefovir.
    Cho Y; Lee DH; Chung KH; Jin E; Lee JH; Cho EJ; Yu SJ; Kim JW; Jeong SH; Yoon JH; Lee HS; Kim CY; Kim YJ
    Dig Dis Sci; 2013 May; 58(5):1363-70. PubMed ID: 23179155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B.
    Dakin H; Bentley A; Dusheiko G
    Value Health; 2010 Dec; 13(8):922-33. PubMed ID: 20825619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B: combined lamivudine and adefovir, and 1-mg entecavir.
    Ze E; Baek EK; Lee JJ; Chung HW; Ahn DG; Cho HJ; Kwon JC; Kim HJ; Lee H
    Clin Mol Hepatol; 2014 Sep; 20(3):267-73. PubMed ID: 25320730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of re-treatment outcomes of lamivudine plus adefovir or entecavir in chronic hepatitis B patients with viral relapse after cessation of adefovir.
    Wang JC; He LL; Chen Q
    Eur Rev Med Pharmacol Sci; 2013 May; 17(9):1162-6. PubMed ID: 23690184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Tenofovir-based Rescue Therapy in Lamivudine-resistant Chronic Hepatitis B Patients With Failure of Lamivudine and Adefovir Combination.
    Park JH; Jung SW; Park NH; Park BR; Kim MH; Kim CJ; Lee BU; Jeong ID; Kim BG; Bang SJ; Shin JW
    Clin Ther; 2015 Jul; 37(7):1433-42. PubMed ID: 25956353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.
    Yang DH; Xie YJ; Zhao NF; Pan HY; Li MW; Huang HJ
    World J Gastroenterol; 2015 Mar; 21(9):2746-53. PubMed ID: 25759545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation.
    Jones J; Shepherd J; Baxter L; Gospodarevskaya E; Hartwell D; Harris P; Price A
    Health Technol Assess; 2009 Jul; 13(35):1-172, iii. PubMed ID: 19607759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis.
    Wu B; Li T; Chen H; Shen J
    Value Health; 2010 Aug; 13(5):592-600. PubMed ID: 20561341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance.
    Wang G; Liu Y; Qiu P; Zhou SF; Xu L; Wen P; Wen J; Xiao X
    Drug Des Devel Ther; 2015; 9():2839-46. PubMed ID: 26082614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and resistance in de novo combination lamivudine and adefovir dipivoxil therapy versus entecavir monotherapy for the treatment-naive patients with chronic hepatitis B: a meta-analysis.
    Liu F; Wang X; Wei F; Hu H; Zhang D; Hu P; Ren H
    Virol J; 2014 Mar; 11():59. PubMed ID: 24673792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of lamivudine plus adefovir therapy versus entecavir with or without adefovir therapy for adefovir-resistant chronic hepatitis B.
    Kang SH; Yim HJ; Kim HR; Kang K; Suh SJ; Lee HJ; Yoon EL; Kim JH; Seo YS; Yeon JE; Byun KS
    J Clin Gastroenterol; 2014; 48(10):889-95. PubMed ID: 24440937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.